bioRxivImmunology
A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding
Abstract
SARS-CoV-2 harbors a unique S1/S2 furin cleavage site within its spike protein, which can be cleaved by furin and other proprotein convertases. Proteolytic activation of SARS-CoV-2 spike protein at the S1/S2 boundary facilitates interaction with host ACE2 receptor for cell entry. To address this, high titer antibody was generated against the SARS-CoV-2-specific furin motif. Using a series of innovative ELISA-based assays, this furin site blocking antibody displayed high sensitivity and specificity for the S1/S2 furin cleavage site, and demonstrated effective blockage of both enzyme-mediated cleavage and spike-ACE2 interaction. The results suggest that immunological blocking of the furin cleavage site may afford a suitable approach to stem proteolytic activation of SARS-CoV-2 spike protein and curtail viral infectivity.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An Innovative antibody-based Plug-and-Play strategy for SARS-CoV-2
J. Tushir-Singh, G. N. Shivange, D. Gogoi·bioRxiv·Mar 11, 2021
- Structural interactions between pandemic SARS-CoV-2 spike glycoprotein and human Furin protease
N. Vankadari·bioRxiv·Apr 10, 2020
- Proteolytic activation of SARS-CoV-2 spike at the S1/S2 boundary: potential role of proteases beyond furin
T. Tang, J. A. Jaimes, … G. R. Whittaker·bioRxiv·Oct 4, 2020
- SARS-CoV-2 spike-glycoprotein processing at S1/S2 and S2' and shedding of the ACE2 viral receptor: roles of Furin and TMPRSS2 and implications for viral infectivity and cell-to-cell fusion
R. Essalmani, J. Jain, … N. G. Seidah·bioRxiv·Dec 18, 2020
- SARS-CoV-2 S protein ACE2 interaction reveals novel allosteric targets
G. S. Anand, R. Palur, … P. A. McAry·bioRxiv·Oct 13, 2020
- Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
A. C. Walls, Y.-J. Park, … D. Veesler·bioRxiv·Feb 19, 2020